TNSN05104A1 - Derives de thiazole pour le traitement de troubles neurodegeneratifs - Google Patents

Derives de thiazole pour le traitement de troubles neurodegeneratifs

Info

Publication number
TNSN05104A1
TNSN05104A1 TNP2005000104A TNSN05104A TNSN05104A1 TN SN05104 A1 TNSN05104 A1 TN SN05104A1 TN P2005000104 A TNP2005000104 A TN P2005000104A TN SN05104 A TNSN05104 A TN SN05104A TN SN05104 A1 TNSN05104 A1 TN SN05104A1
Authority
TN
Tunisia
Prior art keywords
treatment
neurodegenerative disorders
thiazole derivatives
formula
compounds
Prior art date
Application number
TNP2005000104A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Michael Leon Corman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN05104A1 publication Critical patent/TNSN05104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention propose des composés de formule (I) : Dans laquelle R1, R2, R3, R4, R6, R7 et A sont tels que définis. Les composés de formule (I) ont une activité inhibitrice de production du peptide AB. La présente invention propose également des compositions pharmaceutiques et méthodes pour le traitement de maladies, par exemple de la maladie d'Alzheimer, chez des mammifères, comprenant des composés de formule (I).
TNP2005000104A 2002-10-09 2005-04-08 Derives de thiazole pour le traitement de troubles neurodegeneratifs TNSN05104A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
PCT/IB2003/004330 WO2004033439A1 (fr) 2002-10-09 2003-09-29 Composes thiazole utiles pour le traitement des maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
TNSN05104A1 true TNSN05104A1 (fr) 2007-05-14

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000104A TNSN05104A1 (fr) 2002-10-09 2005-04-08 Derives de thiazole pour le traitement de troubles neurodegeneratifs

Country Status (28)

Country Link
US (1) US20040152747A1 (fr)
EP (1) EP1551815A1 (fr)
JP (1) JP2006504796A (fr)
KR (1) KR20050070046A (fr)
CN (1) CN1688557A (fr)
AP (1) AP2005003274A0 (fr)
AR (1) AR043051A1 (fr)
AU (1) AU2003265068A1 (fr)
BR (1) BR0314611A (fr)
CA (1) CA2501803A1 (fr)
CO (1) CO5550435A2 (fr)
CR (1) CR7785A (fr)
EC (1) ECSP055719A (fr)
GT (1) GT200300219A (fr)
IS (1) IS7738A (fr)
MA (1) MA27451A1 (fr)
MX (1) MXPA05002420A (fr)
NL (1) NL1024499C2 (fr)
NO (1) NO20052223L (fr)
OA (1) OA12937A (fr)
PA (1) PA8585001A1 (fr)
PE (1) PE20040640A1 (fr)
PL (1) PL376171A1 (fr)
TN (1) TNSN05104A1 (fr)
TW (1) TW200420550A (fr)
UY (1) UY28011A1 (fr)
WO (1) WO2004033439A1 (fr)
ZA (1) ZA200502841B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2004099200A1 (fr) 2003-05-12 2004-11-18 Pfizer Products Inc. Composes isoxazoliques et isothiazoliques destines au traitement de troubles neurodegeneratifs
EP1653952A4 (fr) * 2003-08-06 2007-04-04 Pfizer Prod Inc Composes d'oxazole destines au traitement de troubles neurodegenerescents
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2007517840A (ja) 2004-01-16 2007-07-05 サノフイ−アベンテイス アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2005073202A1 (fr) 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0509069B8 (pt) * 2004-03-23 2021-05-25 Pfizer Prod Inc compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
CA2575466A1 (fr) 2004-08-13 2006-02-23 Genentech, Inc. Composes a base de 2-amido-thiazole presentant une activite inhibitrice enzymatique utilisant de l'adenosine triphosphate (atp), et compositions, et leurs utilisations
JP5203937B2 (ja) * 2005-05-24 2013-06-05 メルク セローノ ソシエテ アノニム チアゾール誘導体及びその使用
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
RS20080139A (en) * 2005-09-22 2009-05-06 Pfizer Products Inc., Imidazole coumpounds for the treatment of neurological disorders
CA2631750A1 (fr) 2005-12-01 2007-06-07 The Scripps Research Institute Compositions et procedes servant a induire la differenciation neuronale
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
EP1918286B1 (fr) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiaolhydrazides et leur utilisation pour le traitement de maladies neurodegeneratives
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (fr) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activité de pkb
EP2548618A3 (fr) * 2008-07-15 2013-02-27 Novartis AG Dérivés d'hétéroaryle en tant qu'inhibiteurs de DGAT1
WO2010096371A2 (fr) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Composés hétérocycliques qui modulent le récepteur cb2
WO2010126002A1 (fr) * 2009-04-28 2010-11-04 塩野義製薬株式会社 Produit pharmaceutique contenant un composé sulfonamide hétérocyclique
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (fr) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Composés qui modulent le récepteur cb2
WO2012012307A1 (fr) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Composés sulfonylés qui modulent le récepteur cb2
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021360A1 (fr) * 1991-05-28 1992-12-10 Merck & Co., Inc. Derives substitues n-carboxyalkylpeptidyle en tant qu'agents antidegeneratifs
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NO20052223D0 (no) 2005-05-06
BR0314611A (pt) 2005-07-26
US20040152747A1 (en) 2004-08-05
EP1551815A1 (fr) 2005-07-13
GT200300219A (es) 2004-05-18
CA2501803A1 (fr) 2004-04-22
NL1024499A1 (nl) 2004-04-13
PA8585001A1 (es) 2004-12-16
ZA200502841B (en) 2006-03-29
NL1024499C2 (nl) 2004-10-13
MA27451A1 (fr) 2005-07-01
KR20050070046A (ko) 2005-07-05
MXPA05002420A (es) 2005-10-05
PL376171A1 (en) 2005-12-27
WO2004033439A1 (fr) 2004-04-22
TW200420550A (en) 2004-10-16
CO5550435A2 (es) 2005-08-31
CR7785A (es) 2005-07-08
NO20052223L (no) 2005-07-04
AU2003265068A1 (en) 2004-05-04
ECSP055719A (es) 2005-07-06
IS7738A (is) 2005-03-10
AR043051A1 (es) 2005-07-13
OA12937A (en) 2006-10-13
PE20040640A1 (es) 2004-09-15
UY28011A1 (es) 2004-04-30
AP2005003274A0 (en) 2005-06-30
CN1688557A (zh) 2005-10-26
JP2006504796A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
TNSN06300A1 (fr) Derives d'imidazole pour le traitement de troubles neurodegeneratifs
MA27132A1 (fr) Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
MA27472A1 (fr) Acetyle 2-hydroxy-1, 3 diaminoalcanes
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2501799A1 (fr) Composes pyrazole pour le traitement de maladies neurodegeneratives
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA27079A1 (fr) Derives 1, 6-naphthyridine et leur utilisation dans le traitement du diabete et de troubles associes
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
TNSN06314A1 (fr) Sulfonamides destines au traitement de troubles neurodegeneratifs
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
DE69811905D1 (de) Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel
MA29793B1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques.
ATE403428T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren